ARS Pharmaceuticals is burning $72.2 million in SG&A to generate $17.5 million in U.S. net product revenue — a 4:1 spending inversion that is either the cost of building a durable franchise or a warning sign that neffy’s commercial trajectory hasn’t yet justified its infrastructure. The answer hinges almost entirely on one near-term event: CVS Caremark’s formulary decision, expected in early June, which would open unrestricted commercial access at a gross-to-net retention the company has already confirmed sits within its roughly 50% target. Without that coverage, the $199 point-of-sale cash conversion program is a clever patch, not a structural fix.
The unit economics tell a nuanced story. The 28,000 prescribers sound impressive until you recognize that approximately half are repeat prescribers — meaning the other 14,000 wrote once and haven’t returned. Prescribing is also concentrated in the highest-decile accounts, which is typical of a launch phase but signals that broad prescriber adoption is still aspirational. The sales force expansion from 106 to 148 representatives, funded through reallocation rather than new cash, was a disciplined move — but it deepens coverage among allergists who are already engaged, not the mid-tier PCPs or pediatricians who could drive volume at scale. Renewal layering in the second half of 2026 is the mechanism by which ARS expects revenue to compound, and that thesis is untested against a formulary landscape where nine state Medicaid plans is real progress but commercial payer access remains incomplete.
The international picture adds texture without adding near-term revenue. The $2.5 million ALK milestone from the EU 1 mg approval is accounting noise against a $60.6 million quarterly net loss. Health Canada approval and EU authorization for the pediatric 1 mg dose extend the franchise’s addressable geography, but ALK controls commercialization in both markets, so ARS captures economics only through royalties and milestones — a structural ceiling on upside from those regions. The $201 million cash position is a genuine buffer, and management’s confidence that it funds operations through cash-flow break-even is credible only if the CVS Caremark deal closes and renewal prescriptions materialize as projected.
The single marker that determines whether the 4:1 spend ratio looks prescient or reckless is the CVS Caremark formulary confirmation in early June — specifically whether it comes without prior authorization, because that condition is what converts access into actual dispensed prescriptions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
